Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for ...
Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...
The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle ...
The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results